1. Scrip
  2. >>Business
  3. >>Financing

'Game Changing' Apitope Plans IPO To Progress First-In-Class MS Drug

 
• By Sten Stovall

Belgium-based Apitope seeks funds to progress its pipeline of first-in-class immunotherapies targeting autoimmune diseases.

IPO
Apitope To IPO On EuroNext Brussels For Progressing Autoimmune Therapies • Source: Shutterstock

Apitope aims to tap the Brussels Euronext stock market for funds to progress a promising pipeline of antigen-specific immunotherapies for treating autoimmune diseases, firstly its multiple sclerosis treatment candidate ATX-MS-1467 in relapsing MS.

Founded in 2002 as a spin-out from the University of Bristol, Apitope is now based in Diepenbeek, Belgium where its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO

 
• By Mandy Jackson

Faeth Therapeutics raised $25m to complete a Phase II trial of its PIK3/mTOR-targeting drug combination in endometrial cancer and reported positive Phase II data at ESMO in ovarian cancer with half of the combo.

Cash Bonanza For European Oncology-Based Biotechs

 
• By Kevin Grogan

Adcytherix and Step Pharma join Tubulis in raising funds for their cancer drug projects.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

 
• By Anju Ghangurde

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

Kailera’s $600m Mega-Raise Signals Obesity Boom Is Not Slowing Down

 
• By Manas Mishra and Sushmita Panda

Kailera has chalked up its second massive fund raise in the space of a year as it seeks to begin a global trial of its dual GLP-1/GIP receptor agonist by the end of the year.

More from Business

Industry Excellence Celebrated At Citeline Japan Awards

 
• By Ian Haydock

Excellence, innovation and deal-making across the Japanese biopharma sector were celebrated at the Citeline Japan Awards 2025, held in Tokyo on 21 October.

China’s Next Wave Is First-In-Class Innovation

 
• By Jessica Merrill

Drug development in China was a discussion topic at the BioFuture conference as the country’s R&D investments begin to deliver first-in-class medicines.

Stock Watch: J&J’s $5bn Product Predictions Meet Investor Skepticism

 
• By Andy Smith

Despite announcing sales growth that is currently weathering the storm of one of its biggest losses of exclusivity and a spin-off of its orthopedic division, J&J’s stock price weakened after its earnings announcement. Investors probably wanted more visibility on MFN.